Clinical trials: Steatosis
Liver Disease Chronic, Fibrosis, Liver
Effectiveness of Ultrasound in Liver Stiffness and Fat Quantification
Liver stiffness is a marker for scarring of the liver, which occurs after damage from various liver conditions. Scarring prevents normal liver function and can lead to liver failure.
- Conditions
- Liver Disease Chronic, Fibrosis, Liver, Liver Steatoses, Liver Fat
- Trial name
- NCT06111859
- Testing
- Ultrasound based Elastography and fat quantification
- Where
- United Kingdom
- Volunteers
- 180 people
- Sponsor
- King's College Hospital NHS Trust
Liver Steatosis, Fibrosis, Liver
Endoscopic Ultrasound Shear Wave for Liver Fibrosis in MASLD Patients: The RUMIPAMBA Trial
Currently, there is no description of the contribution of the endoscopic ultrasound (EUS)-guided shear wave elastography (SWE) when describing liver fibrosis in patients with screening criteria of metabolic dysfunction-associated…
- Trial name
- NCT06102980
- Testing
- Transparietal ultrasound (US)-based shear wave elastography (SWE) attenuation measurement, Transparietal ultrasound (US)-based shear wave elastography (SWE) stiffness measurement, Vibration-controlled transient elastography (VCTE) attenuation measurement
- Where
- Ecuador
- Volunteers
- 30 people
- Sponsor
- Instituto Ecuatoriano de Enfermedades Digestivas
Non-alcoholic Fatty Liver Disease
6-week Safety and PD Study in Adults With NAFLD
IN THIS PHASE 2A, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, 3 ARM, PARALLEL- GROUP STUDY, SAFETY, TOLERABILITY, AND PHARMACODYNAMICS OF PF-06835919 ADMINISTERED ONCE DAILY FOR 6 WEEKS WILL BE ASSESSED IN ADULTS WITH…
- Trial name
- NCT03256526
- Testing
- PF-06835919 Low Dose, PF-06835919 High Dose
- Where
- 9 sites in United States
- Volunteers
- 53 people
- Sponsor
- Pfizer
Pre Diabetes, Impaired Glucose Tolerance
Effect of F. Prausnitzii on Glycemic Control
The microbiota is associated with a wide spectrum of diseases including diabetes and non-alcoholic fatty liver disease. In this study we will investigate if the bacteria F.
- Conditions
- Pre Diabetes, Impaired Glucose Tolerance, Non-Alcoholic Fatty Liver Disease
- Trial name
- NCT04938843
- Testing
- F. prausnitzii and D. piger
- Where
- Sweden
- Volunteers
- 176 people, healthy volunteers welcome
- Sponsor
- MetaboGen AB
NASH - Nonalcoholic Steatohepatitis
Non-Invasive Quantification of Liver Health in NASH (N-QUAN)
To evaluate, in patients with suspected NASH referred for liver biopsy, the diagnostic performance of CT1 at discriminating those with NAS≥4 \& F≥2 from those without.
- Trial name
- NCT04054310
- Testing
- Liver Multi Scan
- Where
- 7 sites in United States
- Volunteers
- 225 people
- Sponsor
- Perspectum
Chronic Hepatitis b, NAFLD
Effects of Empagliflozin on Fibrosis and Cirrhosis in Chronic Hepatitis B Patients
Chronic hepatitis B (CHB) affects 257million individuals worldwide. In 2017, it caused around 39.7 million cases of cirrhosis and 0.4 million cirrhosis-related deaths in 2017.
- Conditions
- Chronic Hepatitis b, NAFLD, Cirrhosis, Fibrosis, Liver
- Trial name
- NCT05147090
- Testing
- Empagliflozin 10 MG
- Where
- Hong Kong
- Volunteers
- 106 people
- Sponsor
- The University of Hong Kong
Non-alcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis
Endoscopic Ultrasound(EUS)-Guided TRUCUT Biopsy (EUS-TCB) of Suspected Nonalcoholic Fatty Liver Disease(NAFLD.)
Endoscopic Ultrasound involves the placement of a small flexible camera through the mouth and into the stomach to image various parts of the body.
- Trial name
- NAFLD (NCT00586313)
- Testing
- Tru-cut biopsy, Tru-cut
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Indiana University
Non Alcoholic Steatohepatitis
The Effects of Synbiotics Supplement on Biochemical Factors and Hepatic Fibrosis in Patients With Nonalcoholic Steatohepatitis
To study the effects of synbiotics supplement on lipid profile, liver enzymes, inflammatory factors and hepatic fibrosis in patients with Nonalcoholic Steatohepatitis (NASH), 50 patients who referred to Gastrointestinal (GI)…
- Trial name
- NCT01791959
- Testing
- synbiotic
- Volunteers
- 54 people
- Sponsor
- National Nutrition and Food Technology Institute
Non-Alcoholic Fatty Liver Disease
NAFLD Study: US vs Liver Biopsy
Evaluate the diagnostic accuracy of the new ultrasound software vs hepatic histology, the current reference standard for the diagnosis of NAFLD and NASH in 20 obese patients (BMI> 30) candidates for laparoscopic bariatric surgery…
- Trial name
- NAFLD (NCT04101162)
- Testing
- shear waves elastography; liver biopsy
- Where
- Italy
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- University of Roma La Sapienza
Fatty Liver
A Single Center, Randomized, Open Label, Parallel Group, Phase 3 Study to Evaluate the Efficacy of Dapagliflozin in Subjects With Nonalcoholic Fatty Liver Disease
This trial is a randomized, open label, two-arm, parallel-group, non-used comparator, single center trial to evaluate the efficacy of dapagliflozin in subjects with Nonalcoholic fatty liver disease.
- Trial name
- NCT05308160
- Testing
- Dapagliflozin 10Mg Tab
- Where
- Taiwan
- Volunteers
- 75 people
- Sponsor
- National Taiwan University Hospital
Impaired Glucose Tolerance, Pre-diabetes
Study to Investigate the Pathophysiology of Type 2 Diabetes in Youth
The purpose of the study is to determine the role of beta-cell function and insulin resistance in the development of impaired glucose tolerance (IGT) and type 2 diabetes in children and adolescents who have an increased risk of…
- Conditions
- Impaired Glucose Tolerance, Pre-diabetes, Childhood Obesity, Insulin Resistance
- Trial name
- NCT00536250
- Where
- United States
- Volunteers
- 255 people, healthy volunteers welcome
- Sponsor
- Yale University
Obesity & Overweight, Diabetes Mellitus, Type 2
Chinese Overweight/Obesity Cohort: Metabolic & Comorbidity Risks
This is a nationwide, multi-center, long-term follow-up study of overweight and obese adults in China. The study aims to recruit approximately 26,000 participants across 39 hospitals to better understand how body weight affects…
- Conditions
- Obesity & Overweight, Diabetes Mellitus, Type 2, Hypertension, Non-alcoholic Fatty Liver Disease (MASLD)
- Trial name
- NCT07884903
- Testing
- No intervention; observational assessment only
- Where
- China
- Volunteers
- 25,974 people
- Sponsor
- Shanxi Bethune Hospital
Non-alcoholic Fatty Liver Disease, Insulin Resistance
Selenoprotein P and Non-alcoholic Fatty Liver Disease
The pathogenesis of nonalcoholic fatty liver disease has not been fully elucidated. The most widely supported theory implicates insulin resistance as the key mechanism leading to hepatic steatosis, and perhaps also to…
- Trial name
- NCT01257685
- Where
- South Korea
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Korea University
Fatty Liver
Association Between Fatty Liver and Inflammatory Biomarkers
The newly adapted definition for MASLD includes evidence for hepatic steatosis by imaging or biopsy with at least one of the five cardiometabolic criteria; BMI ≥ 25 kg/m2 (≥23 kg/m2 in Asian) or waist circumference >94 cm in men…
- Trial name
- MASLD (NCT07636915)
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Sohag University
Non-alcoholic Fatty Liver, Non-Alcoholic Fatty Liver Disease
Identification of Liver Fibrosis Biomarkers
Chronic liver disease (CLD) is a major cause of global mortality and morbidity . CLD patients are at an increased risk of developing liver fibrosis (formation of scar tissue), cirrhosis and liver failure and are at significant…
- Conditions
- Non-alcoholic Fatty Liver, Non-Alcoholic Fatty Liver Disease, Non-alcoholic Steatohepatitis
- Trial name
- NCT06819917
- Testing
- Identification of liver fibrosis biomarkers
- Where
- 2 sites in Denmark, Germany
- Volunteers
- 575 people
- Sponsor
- Roche Diagnostics GmbH
Non-Alcoholic Fatty Liver Disease
Macrophage-mediated Inflammation in White Adipose Tissue and Non-alcoholic Fatty Liver Disease.
Non-alcoholic fatty liver disease (NAFLD) is present in one third of the population and due to its potential to cause irreversible liver damage and liver cancer, it is a significant health burden.
- Trial name
- NCT04059068
- Where
- United Kingdom
- Volunteers
- 48 people
- Sponsor
- Imperial College London
Type 2 Diabetes, NAFLD
POLY-unsaturated Fatty Acids in the Preservation of Dietary Effects on Hepatosteatosis and Energy Metabolism in Type 2 Diabetes
Basic treatment of type 2 diabetes should focus on diet, physical activity and lifestyle. Nevertheless, in early and late stage of T2DM, lifestyle intervention is mostly substituted by pharmacological intervention, although…
- Conditions
- Type 2 Diabetes, NAFLD, Obesity, Dyslipidemia
- Trial name
- POLYPHEM (NCT03047668)
- Testing
- diet with/without supplementation
- Where
- Germany
- Volunteers
- 200 people
- Sponsor
- German Institute of Human Nutrition
NAFLD, Alcoholic Hepatitis
EUS Guided Liver Biopsy - Will it Give Better Yield, More Tissue With Less Complication?
Liver biopsy would be done by Endoscopic Ultrasound using Acquire needle.
- Trial name
- NCT04235855
- Testing
- Endoscopic USG guided Liver biopsy, Percutaneous Liver Biopsy
- Where
- India
- Volunteers
- 50 people
- Sponsor
- Asian Institute of Gastroenterology, India
Overweight , Obesity, Type 2 Diabetes Mellitus (T2DM)
Phase 1 Clinical Study of MWN105 Injection in Healthy Chinese Volunteers
This study is a randomized, double-blind, placebo-controlled, single-dose and multiple-dose, dose-escalation phase I clinical trial, aiming to evaluate the safety, tolerability, pharmacokinetic and pharmacodynamic…
- Conditions
- Overweight , Obesity, Type 2 Diabetes Mellitus (T2DM), MASH - Metabolic Dysfunction-Associated Steatohepatitis
- Trial name
- NCT07801313
- Testing
- MWN105
- Where
- China
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- Shanghai Minwei Biotechnology Co., Ltd
Metabolic Dysfunction-Associated Steatohepatitis (MASH)
To Evaluate the Tolerability, Pharmacokinetics, and Pharmacodynamics of IMM-H014 in Patients With MASH
This study will evaluate the tolerability, pharmacokinetics, and pharmacodynamics of consecutive Multiple treatment for 12 weeks（84 Days） in Adult Patients with Metabolic Dysfunction-Associated Steatohepatitis.
- Trial name
- NCT07016633
- Testing
- IMM-H014
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Changchun Intellicrown Pharmaceutical Co. LTD
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.